Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 266-358-7 | CAS number: 66423-13-0
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- other information
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: published data, documentation insufficient for assessment
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Acute MCPP intoxication: report of two cases
- Author:
- Meulenbelt J
- Year:
- 1 988
- Bibliographic source:
- Human Toxicology 7, 289-292
- Reference Type:
- secondary source
- Title:
- No information
- Author:
- The Danish Environmental Protection Agency
- Year:
- 1 998
- Bibliographic source:
- Mecoprop-P, EU Review Programme on active substances in Plant Protection Products, Scientific Evaluation and Assessment, Draft December 1998 (Volume 3, Annex B, ) and Addendum II July 2002; see also SANCO/3065/99-Final, 2003
Materials and methods
Results and discussion
Any other information on results incl. tables
Cited from Mecoprop-P, EU Review Programme on active substances in Plant Protection Products, Scientific Evaluation and Assessment, The Danish Environmental Protection Agency, Draft December 1998 (Volume 3, Annex B) and Addendum II July 2002:
"In one of the patients a plasma level of mecoprop of 298 mg/l was determined 3-4 hours after ingestion. The plasma level decreased with a t½ of about 17 h.
The major clinical finings were coma, muscle cramps, respiratory failure and arterial hypoxemia. Respiratory depression and hypoxemia were thought partly to be due to CNS depression and partly due to aspiration. Both patients developed serious renal failure, probably caused by rhabdomyolysis. Rhabdomyolysis (elevated serum myoglobin and serum aldose activity) was suggested to be secondary to muscle cramps. Both patients developed hyperkalemia as a result of a combination of renal failure, muscle cell damage and metabolic acidosis. (The hyperkalaemia and the acidosis were treated with infusions of glucose/insulin and sodium bicarbonate). Both patients exhibited serious decrease in arterial blood pressure and developed anaemia and thrombocytopenia (the latter resulting in multiple petechia in one of the patients). Caustic mucous lesions were not observed in any of the patients. Both patients survived."
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
